Brenda Cooper

4.9k total citations · 2 hit papers
133 papers, 3.0k citations indexed

About

Brenda Cooper is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Brenda Cooper has authored 133 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Hematology, 50 papers in Oncology and 39 papers in Genetics. Recurrent topics in Brenda Cooper's work include Lymphoma Diagnosis and Treatment (35 papers), Acute Myeloid Leukemia Research (34 papers) and Hematopoietic Stem Cell Transplantation (31 papers). Brenda Cooper is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Acute Myeloid Leukemia Research (34 papers) and Hematopoietic Stem Cell Transplantation (31 papers). Brenda Cooper collaborates with scholars based in United States, Canada and Ireland. Brenda Cooper's co-authors include Hillard M. Lazarus, Stanton L. Gerson, Omer N. Koç, Stephen E. Haynesworth, Arnold I. Caplan, Mary J. Laughlin, Richard J. Creger, H. Kent Holland, Philip L. McCarthy and Andrea Bacigalupo and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Brenda Cooper

126 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy

2000 887 citations Omer N. Koç, Stanton L. Gerson et al. Journal of Clinical Oncology profile →
Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients

2005 607 citations Hillard M. Lazarus, Omer N. Koç et al. profile →

Peers

Countries citing papers authored by Brenda Cooper

Since Specialization

Citations

This map shows the geographic impact of Brenda Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Cooper more than expected).

Fields of papers citing papers by Brenda Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Cooper. The network helps show where Brenda Cooper may publish in the future.

Co-authorship network of co-authors of Brenda Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Brenda Cooper. A scholar is included among the top collaborators of Brenda Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda Cooper. Brenda Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Sarit Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B. Johnston, Alexey V. Danilov, Brenda Cooper, Aleksander Chudnovsky, (unknown), Tao Long, (unknown), Deborah Berg, Lapo Alinari	1
2	A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML) 2024 ·Blood ·John F. DiPersio, Guenther Koehne, Nirali N. Shah, Léa Bernard, Hyung C. Suh, Divya Koura, Miguel‐Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph Maakaron, Michael R. Loken, (unknown), (unknown), Saurabh S. Thosar, Sharon L. Hyzy, Glen Raffel, Brenda Cooper	0
3	Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies 2024 ·Cytometry Part B Clinical Cytometry ·Philip G. Woost, Basem M. William, Brenda Cooper, Masumi Ueda, Folashade Otegbeye, Marcos J. de Lima, David N. Wald, Reda Z. Mahfouz, Yogen Saunthararajah, Tammy Stefan, James W. Jacobberger	0
4	Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens 2023 ·Frontiers in Oncology ·Jiasheng Wang, (unknown), Amin Firoozmand, Pingfu Fu, (unknown), (unknown), Marcos de Lima, Kirsten M Boughan, Brenda Cooper, Paolo F. Caimi, Molly Gallogly, Folashade Otegbeye, Benjamin Tomlinson, Leland Metheny	2
5	Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML 2023 ·Journal of Clinical Oncology ·Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, Nikolai A. Podoltsev, José C. Cruz, Tara L. Lin, Gary J. Schiller, Joseph G. Jurcic, Adam Asch, (unknown), Jason E. Hill, Stanley C. Gill, (unknown), Elizabeth Rich, Nahla Hasabou, Alexander E. Perl, Mark J. Levis	27
6	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data 2021 ·Blood ·Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, (unknown), (unknown), Bo H. Chao, Allison Berger, John F. Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda Cooper, Paolo F. Caimi	4
7	Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria 2021 ·Bone Marrow Transplantation ·Nausheen Ahmed, (unknown), Patricio Rojas, Fahrettin Covut, (unknown), (unknown), Ehsan Malek, Leland Metheny, (unknown), Paolo F. Caimi, Marcos de Lima, Brenda Cooper	2
8	Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma 2020 ·Blood ·Brian T. Hill, Deepa Jagadeesh, Alex Garcia, Robert M. Dean, Omer N. Koç, Matt Kalaycio, Kirsten M Boughan, Brenda Cooper, Allison Winter, Wesam Ahmed, Brad Pohlman, (unknown), (unknown), (unknown), Paolo F. Caimi, Mitchell R. Smith	1
9	A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia 2017 ·Blood ·Molly Gallogly, (unknown), (unknown), Paolo F. Caimi, Michael Craig, Marcos de Lima, Stanton L. Gerson, (unknown), Hillard M. Lazarus, Mark J. Levis, Ehsan Malek, Jane A. Little, (unknown), Willem J. van Heeckeren, William Tse, Brenda Cooper	4
10	Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival 2017 ·Blood ·Suchitra Sundaram, (unknown), Benjamin Tomlinson, Richard J. Creger, Ehsan Malek, Leland Metheny, Brenda Cooper, Hillard M. Lazarus, Marcos de Lima, Paolo F. Caimi	2
11	Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies 2011 ·Bone Marrow Transplantation ·Tamila L. Kindwall‐Keller, (unknown), Howard Meyerson, Seunghee Margevicius, Pingfu Fu, (unknown), Hillard M. Lazarus, Brenda Cooper, Stanton L. Gerson, Paul M. Barr, William Tse, (unknown), Laura R. Fanning, Richard J. Creger, (unknown), Mary J. Laughlin	42
12	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors 2009 ·Investigational New Drugs ·Charles Nock, Joanna M. Brell, Joseph A. Bokar, Matthew M. Cooney, Brenda Cooper, Joseph Gibbons, Smitha Krishnamurthi, Sudhir Manda, P. Savvides, Scot C. Remick, Percy Ivy, Afshin Dowlati	17
13	Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant 2009 ·American Journal of Hematology ·Paul M. Barr, Hillard M. Lazarus, Brenda Cooper, Mark Schluchter, Ashok Panneerselvam, James W. Jacobberger, Jack W. Hsu, Nalini Janakiraman, (unknown), Afshin Dowlati, Scot C. Remick	54
14	A Case of CD30+ Nasal Natural Killer/T-Cell Lymphoma 2008 ·American Journal of Dermatopathology ·Katalin Ferenczi, (unknown), (unknown), Brenda Cooper, Howard Meyerson, Kevin D. Cooper, Kord Honda	14
15	Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults 2007 ·British Journal of Haematology ·Willem J. van Heeckeren, Laura R. Fanning, Howard Meyerson, Pingfu Fu, Hillard M. Lazarus, Brenda Cooper, William Tse, Tamila L. Kindwall‐Keller, Jennifer Jaroscak, (unknown), Robert M. Fox, Luis A. Solchaga, (unknown), Richard J. Creger, Mary J. Laughlin	21
16	Randomised comparison of two B‐cell purging protocols for patients with B‐cell non‐Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34⁺ cell enrichment device 2005 ·British Journal of Haematology ·Willem J. van Heeckeren, (unknown), Pingfu Fu, Brenda Cooper, Howard Meyerson, Hillard M. Lazarus, (unknown), Mary J. Laughlin, Stanton L. Gerson, Omer N. Koç	22
17	A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia 2002 ·Leukemia Research ·Brenda Cooper, (unknown), Hillard M. Lazarus, Sylvan B. Green, (unknown), Nancy S. Rosenthal, Sosamma J. Berger, Xiaolin Li, Stephen T. Ingalls, Charles L. Hoppel, Stanton L. Gerson	9
18	Comparative Analysis of Breast Cancer Contamination in Mobilized and Nonmobilized Hematopoietic Grafts 1996 ·Journal of Hematotherapy ·(unknown), (unknown), (unknown), José Luís Passos‐Coelho, John M. Davis, A M Huelskamp, Stephen J. Noga, Nancy E. Davidson, Esther M. John, Brenda Cooper, S L Gerson, H M Lazarus, Kent Holland, Stefan Glück, TJ Moss, (unknown), Linda T. Vahdat, Karen H. Antman	11
19	Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients 1996 ·International Journal of Antimicrobial Agents ·Hillard M. Lazarus, Richard J. Creger, Rasim Gucalp, Robert M. Fox, Niculae Ciobanu, (unknown), Brenda Cooper, M R Jacobs	3
20	An inflammatory eruption associated with recombinant human IL-6 1994 ·British Journal of Dermatology ·(unknown), (unknown), (unknown), Brenda Cooper, M. Zaim, Hillard M. Lazarus, Craig A. Elmets	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact